Climb Bio, Inc.
CLYM · XNASCIK 1768446fmd_0YD1S815K77J4MR6T9TRW1DF5QManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Research and development | 9 | 23 | 26 | 15 | 14 | 47 |
| Total operating expenses | 21 | 36 | 45 | 40 | 82 | 68 |
| Operating income | (21) | (36) | (45) | (40) | (82) | (68) |
| Interest and investment income | – | – | – | – | 8 | 8 |
| Other non-operating income (expense) | 0 | (12) | (0) | 5 | 8 | 8 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | (21) | (47) | (45) | (35) | (74) | (60) |
| Net income to common shareholders | (23) | (52) | (45) | – | – | – |